Axsome Therapeutics (AXSM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Axsome Therapeutics (AXSM)

AXSM 153.85

-0.2%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	12/20/2017 12:53:45 PM
	of 32

2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL Axsome Therapeutics (AXSM) Market Cap: $120 M Cash $40 M Price: $4.75 Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions) Presentation from mid November (see slide 36 for upcoming milestones) media.corporate-ir.net Anticipated Near-Term Clinical Milestones • Clinical Trial Readouts: Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018) Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018) Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018) Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017 themarketsdaily.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next